Dec, 2009

U.S.A.
News / Therapeutic Area News
FDA Advisory Committee Recommends Against Approving Tarceva for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
GAITHERSBURG, Md., Dec 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced...
Read More

Nov, 2009

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y., Nov 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva(R)...
Read More
U.S.A.
News / Therapeutic Area News
Theravance and Astellas Announce the Commercial Launch of VIBATIV™ (telavancin) in the United States
SOUTH SAN FRANCISCO, CA and DEERFIELD, IL – November 5, 2009 – Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today the commercial launch of VIBATIV™ (telavancin) in...
Read More

Oct, 2009

U.S.A.
News / Therapeutic Area News
Cardiome and Astellas Announce Initiation of Patient Enrollment in Act 5 Trial
Vancouver, Canada and Deerfield, Illinois, USA, October 28, 2009 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”)...
Read More
U.S.A.
News / Therapeutic Area News
Zogenix and Astellas Announce Data Published Showing The Benefits of Sumavel™ Dosepro™ Needle-Free Delivery System
SAN DIEGO, CA and Deerfield, IL - (October 22, 2009): Zogenix, Inc. (“Zogenix”), a privately held pharmaceutical company, and Astellas Pharma US, Inc. (“Astellas”) announced that positive...
Read More